No adverse effects were noted in clinical trials (ulcerative colitis, phase II) [84,85], and in toxicological studies, a lethal dose (LD1) was not achieved (for review, see [11,12,13,14,24,25])
The following dosing protocol for healing with TB-500 is not supported by any studies published thus far, but it can serve as a starting point for researchers, who are advised to begin with still lower doses and titrate upward approaching this protocol: Daily Dose: 2mg, administered subcutaneously Frequency: Daily subcutaneous injections Study Duration: 15 days Notes: Researchers need three vials of TB-500 10mg to complete this protocol
Les essentiels ne pas oublier Le DSIP (Delta Sleep-Inducing Peptide) est un nonapeptide endogene de sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, de masse moleculaire 848,81 Da, isole pour la premiere fois en 1977 par l'equipe de Guido Schoenenberger et Marcel Monnier a l'Universite de Berne, a partir du sang veineux cerebral de lapins places en etat de sommeil par stimulation thalamique a basse frequence
Supplied in sealed laboratory vials, the material is intended for analytical investigation, assay development, and experimental applications in professional research environments where documentation and reproducibility are required
Oral: Remarkably, BPC-157 retains bioactivity when administered orally
